We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic (HOLX) Stock Drops Despite Market Gains: Important Facts to Note
Read MoreHide Full Article
Hologic (HOLX - Free Report) closed the most recent trading day at $70.20, moving -0.13% from the previous trading session. This change lagged the S&P 500's daily gain of 0.12%. Meanwhile, the Dow experienced a rise of 0.52%, and the technology-dominated Nasdaq saw a decrease of 0.23%.
The medical device maker's shares have seen a decrease of 2.97% over the last month, not keeping up with the Medical sector's loss of 2.25% and outstripping the S&P 500's loss of 3.45%.
Analysts and investors alike will be keeping a close eye on the performance of Hologic in its upcoming earnings disclosure. The company's earnings report is set to go public on February 5, 2025. It is anticipated that the company will report an EPS of $1.01, marking a 3.06% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $1.03 billion, up 1.39% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $4.28 per share and a revenue of $4.17 billion, demonstrating changes of +4.9% and +3.48%, respectively, from the preceding year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Hologic. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.16% fall in the Zacks Consensus EPS estimate. Hologic presently features a Zacks Rank of #3 (Hold).
In the context of valuation, Hologic is at present trading with a Forward P/E ratio of 16.43. For comparison, its industry has an average Forward P/E of 28.11, which means Hologic is trading at a discount to the group.
Also, we should mention that HOLX has a PEG ratio of 2.39. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Medical - Instruments industry was having an average PEG ratio of 2.06.
The Medical - Instruments industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 77, positioning it in the top 31% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hologic (HOLX) Stock Drops Despite Market Gains: Important Facts to Note
Hologic (HOLX - Free Report) closed the most recent trading day at $70.20, moving -0.13% from the previous trading session. This change lagged the S&P 500's daily gain of 0.12%. Meanwhile, the Dow experienced a rise of 0.52%, and the technology-dominated Nasdaq saw a decrease of 0.23%.
The medical device maker's shares have seen a decrease of 2.97% over the last month, not keeping up with the Medical sector's loss of 2.25% and outstripping the S&P 500's loss of 3.45%.
Analysts and investors alike will be keeping a close eye on the performance of Hologic in its upcoming earnings disclosure. The company's earnings report is set to go public on February 5, 2025. It is anticipated that the company will report an EPS of $1.01, marking a 3.06% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $1.03 billion, up 1.39% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $4.28 per share and a revenue of $4.17 billion, demonstrating changes of +4.9% and +3.48%, respectively, from the preceding year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Hologic. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.16% fall in the Zacks Consensus EPS estimate. Hologic presently features a Zacks Rank of #3 (Hold).
In the context of valuation, Hologic is at present trading with a Forward P/E ratio of 16.43. For comparison, its industry has an average Forward P/E of 28.11, which means Hologic is trading at a discount to the group.
Also, we should mention that HOLX has a PEG ratio of 2.39. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Medical - Instruments industry was having an average PEG ratio of 2.06.
The Medical - Instruments industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 77, positioning it in the top 31% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.